Sanofi, Re­gen­eron prep an­oth­er FDA sub­mis­sion for Dupix­ent, this time for a rare skin con­di­tion

Sanofi and Re­gen­eron’s Dupix­ent hit all end­points in a tri­al eval­u­at­ing the IL4 and IL13 in­hibitor in pa­tients with bul­lous pem­phigoid, a rare skin con­di­tion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER